Abstract Library

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#4390 FDG uptake in lung neuroendocrine tumours and its association with tumour characteristics and prognosis

Introduction: The utility of fluorodeoxyglucose positron emission tomography (FDG-PET) in the evaluation of lung neuroendocrine tumours (L-NETs) remains debated.

Conference:

Presenting Author:

Authors: Twito O, Muzykovskaia E, Frenkel M,

Keywords: lung neuroendocrine tumour, imaging, FDG-PET,

#4368 Surgical and multidisciplinary management of pancreatic neuroendocrine tumours with liver metastases: Insights from a high-volume centre

Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare, with liver metastases posing significant prognostic challenges. MEN1-associated pNETs often present with multifocal and complex disease, requiring a tailored, multidisciplinary approach.

Conference:

Presenting Author: Yuntao B

Authors: Yuntao B, Chunhui Y, Lei L,

Keywords: Pancreatic Neuroendocrine Tumour, Liver Metastasis, MEN1, Multidisciplinary Team, Surgical Resection, Ki-67 Index, SSA, PRRT,

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#3844 Post-partum insulinoma in a MEN1 patient submitted to pancreatic electroporation

Introduction: Pancreatic neuroendocrine tumors (panNET) are a frequent manifestation of MEN1 syndrome. Insulinomas are often surgically treated.

Conference:

Presenting Author: Gil-Santos S

Authors: Gil-Santos S, Santos A, Carvalho A, Oliveira J, Souteiro P,

Keywords: insulinoma, electroporation, pancreatic neuroendocrine tumor, MEN1,